Technical Analysis for PRRUF - Immutep Ltd
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | N/A | N/A | Down |
Historical PRRUF trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 3.15% | |
Hot IPO Pullback | Bullish Swing Setup | 3.15% | |
Narrow Range Bar | Range Contraction | 3.15% | |
Wide Bands | Range Expansion | 3.15% | |
Gapped Down | Weakness | 3.15% | |
Lower Bollinger Band Touch | Weakness | 3.15% | |
20 DMA Resistance | Bearish | -1.67% |
Get a Trading Sidekick!
Immutep Ltd Description
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), which is in a Phase II and Phase I clinical trials for the treatment of metastatic breast cancer and solid tumors. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP701 for cancer; and IMP731 and IMP761 for autoimmune disease. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Classification
Keywords: Biotechnology Cancer Clinical Medicine Drugs Treatment Of Cancer Breast Cancer Autoimmune Diseases Solid Tumors Therapeutic Product Autoimmune Disease Cancer Immunotherapy Cancer Treatments Activation Therapeutic Products Alpha T Cell Melanoma L1 Antineoplastic Drugs Biological Products Thk Immunotherapeutic Metastatic Breast Cancer Glaxosmithkline Lymphocyte Metastatic Melanoma Novartis Immunotherapeutic Products Immutep Orphan Drugs Treatment Of Metastatic Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.8 |
52 Week Low | 0.135 |
Average Volume | 62,190 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.0000 |
20-Day Moving Average | 0.3075 |
10-Day Moving Average | 0.2996 |
Average True Range | 0.0777 |
ADX | 54.9 |
+DI | 38.5939 |
-DI | 15.7265 |
Chandelier Exit (Long, 3 ATRs ) | 0.1969 |
Chandelier Exit (Short, 3 ATRs ) | 0.4831 |
Upper Bollinger Band | 0.3499 |
Lower Bollinger Band | 0.2651 |
Percent B (%b) | 0.35 |
BandWidth | 27.5772 |
MACD Line | -0.0293 |
MACD Signal Line | -0.0293 |
MACD Histogram | 0.0 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.2950 | ||||
Resistance 3 (R3) | 0.2950 | 0.2950 | 0.2950 | ||
Resistance 2 (R2) | 0.2950 | 0.2950 | 0.2950 | 0.2950 | |
Resistance 1 (R1) | 0.2950 | 0.2950 | 0.2950 | 0.2950 | 0.2950 |
Pivot Point | 0.2950 | 0.2950 | 0.2950 | 0.2950 | 0.2950 |
Support 1 (S1) | 0.2950 | 0.2950 | 0.2950 | 0.2950 | 0.2950 |
Support 2 (S2) | 0.2950 | 0.2950 | 0.2950 | 0.2950 | |
Support 3 (S3) | 0.2950 | 0.2950 | 0.2950 | ||
Support 4 (S4) | 0.2950 |